Updated results of a randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC): efficacy and safety

被引：0
|
作者：
Robert, Nicholas [1 ]
Leyland-Jones, Brian [2 ]
Asmar, Lina [1 ]
Belt, Robert [1 ]
Ilegbodu, Des [1 ]
Loesch, David [1 ]
Raju, Robert [1 ]
Cobleigh, Melody [3 ]
Albain, Kathy [4 ]
Slamon, Dennis [5 ]
机构：
[1] US Oncol, Res Dept, Houston, TX USA
[2] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[3] Breast Ctr, Chicago, IL USA
[4] Loyola Univ, Maywood, IL 60153 USA
[5] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Valentine, Elizabeth
    Sayre, Robert
    Cobleigh, Melody
    Albain, Kathy
    McCullough, Cecelia
    Fuchs, Lea
    Slamon, Dennis
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2786 - 2792
  • [2] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
    Rober, NJ
    Leyland-Jones, B
    Asmar, L
    Belt, RJ
    Ilegbodu, D
    Loesch, DM
    Raju, RN
    Cobleigh, M
    Albain, KS
    Slamom, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 20S - 20S
  • [3] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Theodoulou, Maria
    Goldfarb, Shari Beth
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Sklarin, Nancy T.
    Comen, Elizabeth Anne
    Fasano, Julie
    Gajria, Devika
    Drullinsky, Pamela
    Murphy, Conleth G.
    Syldor, Angemael
    Patil, Sujata
    Liu, Jennifer
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [4] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Datko, F.
    D'Andrea, G.
    Dickler, M.
    Theodoulou, M.
    Goldfarb, S.
    Lake, D.
    Fornier, M.
    Modi, S.
    Sklarin, N.
    Comen, E.
    Fasano, J.
    Gajria, D.
    Drullinsky, P.
    Gilewski, T.
    Murphy, C.
    Syldor, A.
    Lau, A.
    Hamilton, N.
    Patil, S.
    Liu, J.
    Chandarlapaty, S.
    Hudis, C.
    Dang, C.
    CANCER RESEARCH, 2012, 72
  • [6] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [7] Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Saeki, Toshiaki
    Mukai, Hirofumi
    Aogi, Kenjiro
    Shigekawa, Takashi
    Ueda, Shigeto
    Naito, Yoichi
    Matsubara, Nobuaki
    Takashima, Seiki
    Hara, Fumikata
    Yamashita, Tomonari
    Ohwada, Shoichi
    Sasaki, Yasutsuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
    Crown, J. P.
    Moulton, B.
    O'Donovan, N.
    CANCER RESEARCH, 2012, 72
  • [9] Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Smyth, Lillian Mary
    Iyengar, Neil M.
    Chandarlapaty, Sarat
    Sugarman, Steven
    Comen, Elizabeth Anne
    Drullinsky, Pamela
    Sklarin, Nancy T.
    Traina, Tiffany A.
    Troso-Sandoval, Tiffany A.
    Patil, Sujata
    Wasserheit-Lieblich, Carolyn
    Argolo, Daniel Fontes Santos De Teive E.
    Baselga, Jose
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345